Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double Blind, Exploratory, Parallel-group, Placebo-controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy

Next Previous
Trial Profile

A Phase II, Double Blind, Exploratory, Parallel-group, Placebo-controlled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Drisapersen (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Acronyms DEMAND II
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 20 Nov 2015 Results of pooled analysis of patients with comparable key baseline characteristics from this and two other clinical trials (700242352 and 700242354) published in a BioMarin Pharmaceutical media release.
  • 23 Apr 2015 According to BioMarin media release, data presented at the American Academy of Neurology (AAN) Annual Meeting.
  • 21 Apr 2015 Results of a pooled analysis of trials DMD114117 and DMD114876 were presented at the 67th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top